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SUMMARY 
 
Prostaglandin (PG) E2 promotes osteoclastic cell differentiation, but the 
physiological function of PGF2α remains unclear. We examined the physiological effects 
of PGF2α on osteoclast differentiation using a murine cell line, RAW264, and the 
column-purified murine bone marrow cells, both of which are differentiable into 
osteoclast-like multi-nuclear cells. Although PGF2α did not affect the number of 
differentiated osteoclasts, PGF2α reduced the bone resorption activity of osteoclasts 
developed from both cell types in a pit formation assay. Thus, PGF2α inhibits bone 
resorption without affecting the number of osteoclasts, providing a novel molecular 
mechanism underlying bone metabolism.  
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1. INTRODUCTION 
 
 In vertebrates, bone regulates blood Ca2+ levels by storing intravital Ca2+, as well 
as providing somatic support. Bone undergoes repeated resorption by osteoclasts and 
formation by osteoblasts. Bone disease arises when the metabolic balance between bone 
resorption and bone formation collapses. For example, excessive bone resorption from a 
postmenopausal lack of estrogen causes osteoporosis 1. Bone diseases related to aging, 
such as geriatric osteoporosis, are becoming large social problems. Therefore, clarifying 
the mechanisms involved in bone metabolism is extremely important. 
Osteoblast activity is important for osteoclast development 2, 3. The osteoclast 
differentiation-inducing factor, receptor activator of nuclear factor κB ligand (RANKL) 
is expressed on the osteoblast cell membrane and acts on osteoclast precursor cells to 
induce osteoclast development 4, 5. RANKL also promotes the survival of differentiated 
osteoclasts 6. Colony stimulating factor-1 (CSF-1), which is secreted by osteoblasts, is 
also required for osteoclast differentiation and survival 7-9. Prostaglandin (PG) E2, 
parathyroid hormone, and activated vitamin D3 also promote osteoclast differentiation 3, 
10. These molecules induce RANKL cell-surface expression in osteoblasts to promote 
osteoclast differentiation. However, PGE2 can also act directly on PGE2 receptors in 
osteoclasts to promote differentiation 11, 12. 
Four subtypes of PGE2 receptors, EP1, EP2, EP3, and EP4, transmit signals by 
coupling with different G proteins 13. EP2 and EP4 promote cyclic adenosine 
monophosphate (cAMP) production by coupling with Gs protein, whereas EP3 inhibits 
cAMP production by coupling with Gi. EP1 causes elevations in intracellular Ca2+ by 
coupling with Gq 13. Osteoclasts express all PGE2 receptors, and production of 
intracellular Ca2+ through EP1 or production of cAMP and activation of protein kinase 
A (PKA) through EP2 or EP4 are critical for osteoclast cell differentiation 11, 12, 14, 15. 
PGs are lipid mediators that regulate a number of physiological functions. PGE2 
promotes the resorption of bone, and PGI2 inhibits osteoclastic bone resorption, 
suggesting that PGs are critically important in bone metabolism 16, 17, 18. Although there 
were a couple of reports that PGF2α acted on the bone metabolism in organ and 
osteoblasts19, 20, little is known about the physiological roles in osteoclast development. 
PGF2α signals through a specific receptor (FP) 
13, 21. FP activation stimulates Gq, 
leading to phosphatidylinositol hydrolysis by phospholipase C to produce 
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diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) 22, 23. IP3 stimulates 
intracellular Ca2+ release and DAG activates protein kinase C (PKC). Nuclear factor of 
activated T cell c1 (NFATc1) is the master regulator of osteoclast differentiation 24, 25, 
and requires a Ca2+ signal for activation. Since PKC also contributes to osteoclast 
differentiation, PGF2α activity may be involved in this process 
26, 27. 
In this study, we clarified the physiological effects of PGF2α on osteoclast 
development using both a murine RAW264 cell line and the primary bone marrow cells 
that can differentiate into osteoclast-like multi-nuclear cells (MNC). 
 
 
2. MATERIALS AND METHODS 
 
2.1. Expression plasmid 
The expression plasmid (pGEX-2TK-RANKL) for the soluble RANKL-GST fusion 
protein was a gift from Dr. Takeya at the University of Nara Institute of Science and 
Technology 28, 29.  
 
2.2. Cell culture 
RAW264 cells (RIKEN Institute of Physical and Chemical Research cell bank, 
Tsukuba, Ibaraki, Japan) were cultured at 37°C in 90-mm dishes in Dulbecco's modified 
Eagle's medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 
10% FBS (Sanko Junyaku, Chiyoda, Tokyo, Japan) and 1% MEM non-essential amino 
acid solution (NEAA) (Invitrogen, Carlsbad, CA, USA). We obtained mouse myeloid 
cells from femurs and tibiae resected from a 6-week-old male mouse (Saitama 
Experimental Animal Supply, Katsushika, Saitama, Japan). According to the methods of 
Ly and Mishell, myeloid cells were purified using a Sephadex-G10 (GEC, Fairfield, CT, 
USA) column, and the obtained cell population was used for further analysis 30, 31, 32. 
 
2.3. Preparation of GST-RANKL 
The pGEX-2TK-RANKL plasmid, which includes an active RANKL construct, was 
transfected into E. coli JM109. Transduced E. coli were cultured at 37 °C in 1 L Super 
Broth culture medium (25 g/L Trypton Pepton [Becton, Dickinson and Co., Franklin 
Lakes, NJ, USA], 15 g/L Bacto Yeast Extract [Becton, Dickinson], 5 g/L NaCl) with 50 
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µg/mL ampicillin sodium until the OD600 was about 0.75. Expression of GST-RANKL 
was induced by incubating for 8 h with 0.25 mM isopropyl-β-D-thiogalactopyranoside 
at 18 °C 28, 29. 
After centrifuging of the E. coli solution at 3000 ×g at 4 °C for 10 min, the E. coli 
were resuspended in NETN buffer (20 mM Tris·HCl [pH 8.0], 100 mM NaCl, 1 mM 
EDTA, 0.5% NP-40) and disrupted with a Supersonicator. This solution was separated 
by 2nd centrifugation again, and Glutathione Sepharose 4B beads (GEC) were added to 
the supernatant, and then the mixture was incubated at 4 °C for 8 h in a rotary mixer. 
After washing of the beads in PBS four times, 500 µL of glutathione–NaCl buffer (100 
mM Tris·HCl [pH 8.0], 120 mM NaCl, 20 mM glutathione [Wako Pure Chemical, 
Osaka, Japan]) was added, and the mixture was incubated at 4 °C for 2 h to elute the 
GST-RANKL solution. The eluate was mechanically sterilized with a 0.2-µm filter 
(Toyo Roshi, Taitou, Tokyo, Japan), and endotoxin was removed using Detoxi-Gel 
Endotoxin Removing Gel (Pierce Biotechnology, Rockford, IL, USA) 28, 29. 
 
2.4. In vitro osteoclast development 
RAW264 cells were plated on a 96-well plate at 2 × 103 cells/well and cultured in 
Minimum Essential Medium Alpha Medium (α-MEM) (Invitrogen) (10% FBS, 1% 
NEAA) containing 100 ng/mL RANKL and PGF2α (Wako). Cells were used after 5-d 
culture. 
The column-purified bone marrow cells were plated at 1 × 105 cells/well on a 
96-well plate coated with RANKL (final 100 ng/mL) and CSF-1 (final 20 ng/mL). 
Inoculated cells were cultured in α-MEM (10% FBS) containing PGF2α or fluprostenol 
(Sigma-Aldrich), and cells were collected 7 d later for further analysis. 
 
2.5. TRAP assay 
Wells were washed with PBS, and cells were fixed by incubation with 100 µL of 4% 
paraformaldehyde at 4 °C overnight. Each well was washed with distilled water, and 
then 100 µL of tartrate-resistant acid phosphatase (TRAP) solution (50 mM sodium 
tartrate, 45 mM sodium acetate [pH 5.0], 0.01% naphthol AS-MX phosphate 
[Sigma-Aldrich], 0.03% fast red violet LB salt [Sigma-Aldrich]) was added to each well 
and incubated for 10 min 33. Cells were washed with water and observed through an 
optical microscope. 
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2.6. Acridine orange staining 
After cell differentiation, acridine orange (Merck, Whitehouse Station, NJ, USA) 
was added to a final concentration of 5 µg/mL, and cells were cultured for 30 min. 
Stained cells were observed through a fluorescence microscope 34, 35. 
 
2.7. Pit formation assay 
We dismembered the small ivory column with a diameter of 4 mm (Atelier 
Sugimoto, Musashino, Tokyo, Japan) to obtained thin dentin slices, which were 
polished with glass paper and abrasives to 0.3-µm thickness, then washed with a 
supersonicator. These slices were put in 48-well plates, 100% EtOH was added, and the 
dentin was dried with a UV lamp on a clean bench. The dried slices were placed in a 
24-well plate with a few drops of FBS. The slices were soaked for several hours in 
α-MEM, then the medium was removed, and RAW264 cells were plated on the slices at 
5 × 103 cells/well in α-MEM media containing 100 ng/mL RANKL and PGF2α. After 3, 
5, 7, and 9 d in culture, culture medium was replaced; dentin slices were collected after 
11-d culture. 
The column-purified bone marrow cells were spread at 2.5 × 105 cells/well on 
dentin slices coated with RANKL (final 100 ng/mL) and CSF-1 (final 20 ng/mL). Cells 
were cultured in α-MEM containing PGF2α, with medium changes after 2, 5, and 7 d; 
dentin slices were collected after 9 d incubation. 
After culturing, dentin slices were collected and soaked in 0.1% ammonia at 4 °C 
overnight. Cells were removed from the dentin slices with a supersonicator, and the 
slices were dehydrated by 70% to 99% ethanol, dried, and coated with carbon. 
Microscopic examination was performed with a scanning electron microscope. 
 
2.8. PCR analysis 
RAW264 cells were cultured on 60 mm plates, and RNA was extracted by a 
standard acid-GTC-phenol extraction method 11. The cDNA from RAW264 cells was 
synthesized using M-MLV Reverse Transcriptase (Takara Bio, Otsu, Shiga, Japan). The 
cDNA of the column-purified bone marrow cells was also used for PCR analysis. PCR 
(95 °C for 5 min; 18–40 cycles of 95 °C for 30 s, 55 °C for 1 min, 72 °C for 1 min; 
72 °C for 7 min) was performed using the following primers: 
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Glyceraldehyde 3-phospate dehydrogenase (G3PDH) primers: 
 G3PDH-S1 (5′-GACCCCTTCATTGACCT-3′) 
 G3PDH-A1 (5′-CCACCACCCTGTTGCTGT-3′) 
PGF2α receptor (FP) primers: 
 MFP-S1 (5′-AGTCAAAGGCTTCCTTCC-3′) 
 MFP-A1 (5′-GTGACGGCATTGCACGAG-3′) 
Catepsin K (CtpK) primers: 
 mhCtpK-S2 (5′-TCCATACATATGAACTGG-3′) 
 mhCtpk-A2 (5′-TATCCTTTGTTTCCCCAG-3′) 
Calcitonin receptor (CtR) primers: 
 mCTR-S1 (5′-CGAACCTGGTCCAACTATAC-3′) 
 mCTR-A1 (5′-CTTCACAGCCTTCAGGTACA-3′) 
Tartrate-resistant acid phosphatase (TRAP) primers: 
 mTRAP-S1 (5′-CGGGAAATGGCCAATGCCAA-3′) 
 mTRAP-A1 (5′-TAGGCAGTGACCCCGTATGT-3′) 
Matrix metalloproteinase 9 (MMP9) primers: 
 mMMP9-S1 (5′-CTGTCCAGACCAAGGGTACAGCCT-3′) 
 mMMP9-A1 (5′-GAGGTATAGTGGGACACAT-3′) 
Nuclear factor of activated T cell c1 (NFATc1) primers: 
 mNfatC1-S1 (5′-CAACGCCCTGACCACCGATAG-3′) 
 mNfatC1-A1 (5′-GGCTGCCTTCCGTCTCATAGT-3′) 
Receptor activator of nuclear factor κB (RANK) primers: 
 mRANK-S1 (5′-TGTTGCAGCAGATGCGAA-3′) 
 mRANK-A1 (5′-TCTTGCTGACTGGAGGTT-3′) 
 
2.9. Western blotting 
Cells were dissolved in sample buffer (50 mM Tris·HCl [pH 6.8], 2% SDS, 6% 
β-mercaptoethanol, 1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, 1 mM EDTA) with a 
supersonicator. SDS-PAGE was performed with 20 µg of protein, and the separated 
proteins were transferred to a nitrocellulose membrane. The blotted membrane was 
soaked in 5% BSA and incubated with primary antibody for phosphorylated PKC 
(phospho-PKC [pan]  [Cell Signaling Technology, Danvers, MA, USA], 
phospho-PKCα/βII [Cell Signaling Technology], phospho-PKCδ [Cell Signaling 
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Technology], β-actin [SIGMA-Aldrich]), and with a secondary antibody for 
HRP-conjugated anti-rabbit IgG (Cell Signaling Technology). Phospho-PKC (pan) 
detects phosphorylated PKCα, PKCβI, PKCβII, PKCδ, PKCε, and PKCη. 
Phospho-PKCα/βII detects phosphorylated PKCα and PKCβII. Phospho-PKCδ detects 
phosphorylated PKCδ. Finally, each protein band was detected by chemiluminescence 
(Las1000, FujiFILM, Minato, Tokyo Japan). 
 
2.10. Image analysis 
Image analysis was performed using ImageJ, a public domain Java-based 
image-processing program inspired by NIH Image 36. 
 
2.11. Statistical analysis 
Results are expressed as mean ± standard deviation. Comparisons between groups 
were made by analysis of variance (ANOVA), and when significant, were examined by 
Tukey’s all-pairwise-comparison test. Differences were considered significant when P < 
0.05. Statistical analysis was performed using Excel 2004 (Microsoft, Redmond, WA, 
USA) with the add-in software Statcal 2 37. 
 
 
3. RESULTS 
 
3.1. PGF2α influences osteoclast development of the column-purified bone marrow cells 
We examined murine myeloid cells to determine how PGF2α influenced osteoclast 
differentiation under in vivo-like conditions. Mouse bone marrow was resected, and 
cells were purified by passage through a G-10 column. The column-purified cells were 
cultured for 7 d with various concentrations of PGF2α in the presence of 100 ng/mL 
RANKL and 20 ng/ml CSF-1, leading to osteoclast development. Induced osteoclasts 
were specifically dyed by the TRAP method, and the number and size of stained 
osteoclast-like MNC with more than three nuclei were measured (Figs. 1A, B, C). 
PGF2α did not change the number of developed osteoclast (Fig. 1B). PGF2α reduced the 
area occupied by osteoclast (Fig. 1C). Furthermore, an expression of FP in the 
column-purified bone marrow cells was examined by RT-PCR. As shown in Fig. 1D, 
mRNA of FP was expressed significantly, in both pre- and post-osteoclast 
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differentiation. We further examined the physiological action of PGF2α to osteoclast 
development by using fluprostenol, a selective FP agonist. As shown in figure, 
Fluprostenol slightly reduced the number of MNC (Fig. 1E) and reduced the area 
occupied by osteoclast to 40%  (Fig. 1F).  
 
3.2. PGF2α affects the function of the differentiated column-purified bone marrow cells 
We also examined whether PGF2α modified pit formation by using osteoclast 
developed from the column-purified bone marrow cells. Purified myeloid cells were 
cultured on dentin slices for 7 d in the presence of 20 ng/mL CSF-1, 100 ng/mL 
RANKL, and various doses of PGF2α. After differentiation, cells were cultured for 2 
more d with PGF2α to let pit formation proceed on dentin slices. PGF2α 
dose-dependently reduced the size of the pit on the dentin slice formed by 
myeloid-derived osteoclasts (Figs. 2A, 2B). In the acridine orange assay, PGF2α did not 
modulate acid accumulation in osteoclast lysosomes (Fig. 2C). 
 
3.3. PGF2α influences to osteoclast-like development of RAW264 cell 
We next used RAW264 cell that is mouse macrophage-derived cell line. RAW264 
cell differentiates into osteoclast-like MNC in the presence of RANKL 29. We added 
PGF2α to RAW264 cells in the presence of 100 ng/mL RANKL, and after 5 d culture, 
differentiated osteoclasts were detected by TRAP staining. 
Microscopic observation revealed that PGF2α dose-dependently increased the size of 
large MNC (Fig. 3A). As in myeloid cells, PGF2α did not affect the total number of 
MNC (Fig. 3B). But 10–8 M PGF2α increased the surface area covered by MNC 
three-fold ,in contrast to myeloid cells (Fig. 3C).  
 
3.4. PGF2α affects the function of differentiated RAW264 cell 
We also examined whether PGF2α affected bone resorption in differentiated 
RAW264 cell using the pit formation assay. PGF2α was added to dentin slices in the 
presence of 100 ng/ml RANKL for 11 d to induce osteoclast development. As in 
myeloid cells, PGF2α dose-dependently decreased pit area (Fig. 4A, B). Also as in 
myeloid cells, PGF2α did not affect lysosomal H+ levels in RAW264 cell (Fig. 4C). 
 
3.5. FP expression and signal transduction in RAW264 cell 
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We examined whether FP mRNA was expressed in either naive RAW264 cell or 
MNC derived from them. Cells were cultured in the presence or absence of RANKL 
and PGF2α for 1, 5, or 11 d, and RNA prepared from these cells was subjected to 
RT-PCR. FP mRNA was expressed throughout the incubation period (Fig. 5A). 
We then examined whether FP signaling (measured by PKC phosphorylation) was 
activated by PGF2α. RAW264 cells were cultured for 24 h in the presence or absence of 
100 ng/mL RANKL, and then exposed to PGF2α for 30 min. PGF2α dose-dependently 
increased levels of phosphorylated PKCα, PKCβII, and PKCδ in the presence of 
RANKL (Fig. 5B). 
 
3.6. PGF2α does not influence the expression of osteoclast specific genes  
We examined the effects of PGF2α on the expression of mRNAs for 
osteoclast-specific genes by RT-PCR. RAW264 cells were differentiated into osteoclasts 
by the addition of PGF2α and 100 ng/mL RANKL, and RNA was prepared from cells 
cultured for 1, 3, 5, or 7 d. PGF2α did not change mRNA levels of the osteoclast specific 
genes cathepsin K (CtpK), calcitonin receptor (CtR), Tartrate-resistant acid phosphatase 
(TRAP), Matrix metalloproteinase 9 (MMP9), or Nuclear factor of activated T cell c1 
(NFATc1), Receptor activator of nuclear factor κB (RANK) (Fig. 6).  
 
 
4. DISCUSSION 
 
Generally, it is known that PGE2 acts on osteoblasts and induces an expression of 
RANKL, leading to a strong promotion osteoclast development and bone resorption 10. 
In addition, Fujita et al 11 reported that PGE2 directly acts on osteoclast progenitor cell 
too and promotes osteoclast cell differentiation. In this report, we revealed that PGF2α 
acts on precursor osteoclasts or on osteoclasts directly and has the opposite 
physiological function of PGE2 in osteoclast. 
As it was reported by Fujita et al 11, mouse myeloid cells, from which an adhesive 
cell were removed using a G10 column 30, were used for the physiological analysis. 
Myeloid cells include stromal cells, macrophages, and blood corpuscle cells, but 
macrophages and stromal cells, which include osteoblasts and their precursors, are 
removed by passing through a G10 column 31, 32. Because the hematopoietic stem-cells, 
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which are the potential precursor of osteoclast, were included in the column-purified 
myeloid cells fraction, osteoclast differentiation from these cells is easily induced by the 
stimulation of RANKL and CSF-1. Experiment using the column-purified myeloid cells 
revealed that PGF2α reduced the size of MNC (Fig. 1A), but did not increase the total 
number of MNC with three or more nuclei (Fig. 1B). Thus, PGF2α reduced the total 
plate area that MNC occupied (Fig. 1C). In addition, mRNA of FP was expressed in 
both undifferentiated and differentiated-osteoclast (Fig. 1D). As well as PGF2α, FP 
selective agonist Fluprostenol also caused the reduction of MNC size (Fig. 1F), 
suggesting that PGF2α affected to the differentiation osteoclast via FP. Because 
pre-osteoclasts fuse during differentiation, these results possibly suggest that PGF2α 
inhibits pre-osteoclast cell fusion or enlargement of osteoclast via FP signaling. In fact, 
the number of the nuclei in MNC developed from mouse myeloid decreased clearly by 
PGF2α stimulation (data not shown). 
Furthermore, PGF2α suppressed osteoclast-mediated bone resorption in the pit 
formation assay (Fig. 2C). It is known that osteoclasts grow bigger by fusion, and 
thereby resorb bone efficiently 38, 39. Therefore, PGF2α possibly reduced efficiency of 
bone resorption by making small osteoclasts, without influencing it for accumulation of 
intracellular H+ through V-ATPase （Fig. 1, 2）. 
In order to know the physiological action of PGF2α for osteoclasts in detail, mouse 
RAW264, a differentiation-inducible cell line to osteoclasts, was used for analysis. The 
mouse cell line RAW264, a macrophage-like monocyte, can develop into osteoclast-like 
MNC following RANKL stimulation 33, 40. Differentiation to osteoclasts of RAW264 
cell was induced in the presence of PGF2α, and the number and area of osteoclasts were 
measured. As a result, in the same result as myeloid cells, PGF2α did not increase the 
total number of MNC with three or more nuclei (Fig. 3). Furthermore, PGF2α suppressed 
osteoclast-mediated bone resorption in the pit formation assay (Fig. 4A, B). Because 
PGF2α does not induce osteoclast apoptosis (data not shown), these decreases in pit 
formation were not caused by cell death, but may instead reflect a suppression of bone 
resorption itself by osteoclast. However, PGF2α did not affect H+ accumulation in 
lysosomes (Fig. 4C) and did not change the mRNA expression of the osteoclast-specific 
proteases CtpK and MMP9 (Fig. 6). 
The mRNA for FP, the PGF2α receptor, was clearly detected throughout osteoclast 
differentiation of RAW264 (Fig. 5A). As a fact, PGF2α dose-dependently increased 
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phosphorylation levels of classical PKC (PKCα and PKCβII) and novel PKC (PKCδ), 
indicating that the FP signaling pathway was activated in the precense of RANKL (Fig. 
5B). The classical PKC isoforms are activated by Ca2+ and DAG, novel PKCs are 
activated by DAG, and atypical PKCs lack binding sites for Ca2+ and DAG 41. Because 
FP signaling increases Ca2+ and DAG, PGF2α play roles via FP signaling cascade in 
osteoclast differentiation of RAW264. Ca2+ signals could contribute to activation of the 
NFATc1 transcription factor, a master regulator of osteoclastic cell differentiation 42. 
Although we predicted that FP-mediated Ca2+ increases would increase NFATc1 
expression, PGF2α did not affect expression of NFATc1 mRNA or other specific genes 
of osteoclast differentiation, such as CtpK and MMP9. This result supports the data that 
PGF2α did not increase osteoclast number (Fig.1B, 3B), and further suggests that 
NFATc1 and other downstream genes do not contribute to decreased bone resorption by 
PGF2α stimulation. 
In this report, it was suggested that activation of PKC by PGF2α might work in a 
suppression of bone resorption. In general, calcitonin is known as a representative 
molecule inhibiting bone resorption. Calcitonin inhibits bone resorption by activating 
signaling course through PKC, as well as signaling through PKA 43. Because PGF2α 
activates PKC course through FP receptor 22, 23, it is possible that PGF2α inhibits bone 
resorption by activating calcitonin-dependent PKC signaling cascade. Calcitonin 
receptor is expressed only in differentiated-osteoclasts and therefore it is used for an 
marker gene of osteoclastic cell differentiation, however, calcitonin does not influence 
osteoclast cell differentiation in itself 44. In addition, depression effect of bone 
resorption by calcitonin does not persist so that cAMP induced by calcitonin suppresses 
an expression of calcitonin receptor mRNA 45, 46 On the other hand, in contrast to 
calcitonin, because an expression of FP is not influenced at all by PGF2α (Fig. 5A), 
inhibitory effect for bone resorption by PGF2α may act continuously. 
In this study, by a difference of cellular kind, reverse effect of PGF2α for cellular 
size, miniaturization in myeloid cell and enlargement in RAW264 cell, was observed 
(Fig. 1B, 3B). Observation under microscope revealed that a change of the number of 
the nuclei was not almost found in a RAW264 cell whereas the number of the nuclei 
decreased by PGF2α stimulation with myeloid cells clearly (data not shown). Because 
RAW264 cell was established by transformation with Abelson leukemia virus, c-Abl is 
constantly activated with an RAW cell 40. This tyrosine kinase activity of c-Abl may 
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have some influences on effect of PGF2α to RAW264 cell. An activation of tyrosine 
kinase will promote cell spreading of osteoclast 47, therefore, it is possible that 
spreading was promoted than cell miniaturization by PGF2α in RAW264 cell. 
Alternatively, decreased osteoclast area possibly resulted from differences in the cell 
types themselves (e.g., RAW264 vs myeloid cells), or from the influence of blood 
corpuscle cells not removed by the column 48, 49. Therefore, it is possible that indirect 
effect, as well as direct effect, of PGF2α for an osteoclastic progenitor was observed in 
the column-purified myeloid cells. 
Thus, PGF2α acts on precursor osteoclasts or directly on osteoclasts to inhibit bone 
resorption. So far, it was reported that PGF2α induced PGE2 production in the 
cultured-organ, but further analysis of bone-metabolic action of PGF2α is required by 
using the living animal. Therefore, understanding the osteoclast regulatory mechanisms 
downstream of PGF2α is an important future task. 
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CAPTIONS TO ILLUSTRATIONS 
 
Fig. 1. Effect of PGF2α on differentiation of the column-purified myeloid cells into 
osteoclast. The column-purified bone marrow cells prepared from a 6-week-old male 
ddY mouse were cultured with 100 ng/mL RANKL, 20 ng/mL CSF-1, and various 
doses of PGF2α for 7 d. (A) Cells were cultured with 0 M (a), 10
-8 M (b), and 10-6 M (c) 
of PGF2α, fixed with 4% paraformaldehyde solution, and stained by the TRAP method. 
TRAP-positive, multi-nuclear cells (MNC) were observed (×50 magnification). (B) (C) 
Cells were cultured with 0 M, 10-9 M, 10-8 M, 10-7 M, or 10-6 M PGF2α, and the number 
and area of TRAP-positive MNC with more than three nuclei were measured 
(cells/view). Cell size was calculated relative to size at 0 M. An error bar shows 
standard deviation of the mean, n = 6. Against a value of 0 M, * P < 0.05 and ** P < 
0.01. (D) PCR was performed using cDNA of the column-purified bone marrow cells 
before (0 d) and after (7 d) the induction of differentiation. (E) (F) The column-purified 
bone marrow cells were cultured with 0 M, 10-9 M, 10-8 M, 10-7 M, or 10-6 M 
fluprostenol, and the number and area of TRAP-positive MNC with more than three 
nuclei were measured (cells/view). Cell size was calculated relative to size at 0 M. An 
error bar shows standard deviation of the mean, n = 6. Against a value of 0 M, * P < 
0.05. 
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Fig. 2. Effect of PGF2α on bone resorption in osteoclast derived from the 
column-purified bone marrow cells. (A) The column-purified cells prepared from a 
6-week-old male ddY mouse were cultured on dentin slices with 100 ng/mL RANKL, 
20 ng/ml CSF-1, and various doses of PGF2α for 7 d, and then for another 2 d to induce 
pit formation. Cells were cultured with 0 M (a), 10-8 M (b), and 10-6 M (c) PGF2α, and 
dentin slices were treated as described in the Materials and Methods for observation 
under an electron microscope (×20). (B) Cells were cultured on dentin slices with 0 M, 
10-9 M, 10-8 M, 10-7 M, and 10-6 M of PGF2α. After culturing, the pit area was measured 
using image analysis software (ImageJ), and the ratios of total pit area are compared. An 
error bar shows standard deviation of the mean, n = 3. (C) Cells were cultured with 100 
ng/mL RANKL, 20 ng/mL CSF-1, and 0 M (a) or 10-6 M (b) PGF2α for 7 d, and then 
stained by acridine orange. Stained cells were observed under a fluorescence 
microscope (×50). 
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Fig. 3. Effect of PGF2α on differentiation of RAW264 cell into osteoclast. RAW264 
cells were cultured in the presence of 100 ng/mL RANKL and various doses of PGF2α 
for 5 d. (A) Cells were cultured with 0 M (a), 10-8 M (b), and 10-6 M (c) of PGF2α, fixed 
with 4% paraformaldehyde solution, and stained by the TRAP method. TRAP-positive  
MNC observed under microscope are indicated (×50). (B) (C) Cells were cultured with 
0 M, 10-9 M, 10-8 M, 10-7, and 10-6 M of PGF2α, and the number and area of 
TRAP-positive MNC with more than three nuclei were measured (cells/view). Cell size 
is calculated relative to 0 M. An error bar shows standard deviation of the mean, n = 5. 
Against a value of 0 M, ** indicates P < 0.01.
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Fig. 4. Effect of PGF2α on bone resorption of osteoclast derived from RAW264 cell. (A) 
RAW264 cells were cultured on dentin slices in the presence of 100 ng/mL RANKL and 
various doses of PGF2α for 5 d. Cells were then cultured for a further 6 d to induce pit 
formation. Cells were cultured with 0 M (a), 10-8 M (b), and 10-6 M (c) of PGF2α, and 
then dentin slices were treated as described in Materials and Methods for observation 
under a scanning electron microscope (×20). (B) Cells were cultured on dentin slices 
with 0 M, 10-9 M, 10-8 M, 10-7 M, and 10-6 M of PGF2α. After culture, the area of pit 
was measured using image analysis software (ImageJ), and the ratio of the total pit area 
was compared. An error bar shows standard deviation of the mean, n = 3. Against a 
value of 0 M, * P < 0.05. (C) RAW264 cells were cultured with 100 ng/mL RANKL 
and with 0 M (a) or 10-6 M (b) of PGF2α for 5 d, and then stained by acridine orange. 
Stained cells were observed under a fluorescence microscope (×50). 
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Fig. 5. Activation of FP signaling by stimulation with PGF2α. (A) RAW264 cells were 
cultured with RANKL ((–) 0 ng/mL, (+) 100 ng/mL) and PGF2α ((–) 0 M, (+) 10
-8 M), 
and then total RNA was prepared for RT-PCR. PCR was performed with FP-specific 
primers (40 cycles), or G3PDH-specific primers (20 cycles). (B) RAW264 cells were 
cultured for 24 h with RANKL ((–) 0 ng/mL, (+) 100 ng/mL). Cells were then cultured 
with PGF2α (0 M, 10
-8 M, 10-6 M) or 100 nM TPA for 30 min and subjected to Western 
blot analysis. 
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Fig. 6. Expression of osteoclast-specific genes. RAW264 cells were cultured with 
100 ng/mL RANKL and with 0 M, 10-8 M or 10-6 M PGF2α for 1, 3, 5, or 7 d. Total 
RNA was extracted for RT-PCR with specific primers for CtpK (22 cycles), TRAP (22 
cycles), CtR (32 cycles), MMP9 (32 cycles), NFATc1 (20 cycles), RANK (30 cycle) and 
G3PDH (18 cycles). CtpK, cathepsin K; CtR, calcitonin receptor; TRAP, 
tartrate-resistant acid phosphatase; MMP9, matrix metalloproteinase 9; NFATc1, nuclear 
factor of activated T cell c1; RANK, Receptor activator of nuclear factor κB. 
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Fig. S1 PGF2α did not induce apoptosis in osteoclastgenesis. (A) The column-purified bone marrow
cells prepared from a 6-week-old male ddY mouse were cultured with 100 ng/mL RANKL, 20 ng/mL
CSF-1, and various doses of PGF2α for 6 d. Cells were cultured with 0 M (a, c) and 10-6 M (b) of
PGF2a, and stained by the ApopTag® Plus Peroxidase In Situ Apoptosis detection Kit (CHEMICON,
Billerica, MA, USA).  A positive control sample was prepared by treating DNase I (c). Apoptosis-
negative, multi-nuclear cells (MNC) were observed (×400 magnification). (B) RAW264 cells were
cultured with 100 ng/mL RANKL and various doses of PGF2α for 4 d. Cells were cultured with 0 M (a,
c) and 10-6 M (b) of PGF2a, and stained by the ApopTag® Plus Peroxidase In Situ Apoptosis detection
Kit.  A positive control sample was prepared by treating DNase I (c). Apoptosis-negative, multi-nuclear
cells (MNC) were observed (×400 magnification).
